Brief: Novan Submits NDA To U.S. FDA For Berdazimer Gel, 10.3%

Ligand Pharmaceuticals Incorporated

06/01/2023 13:23

Jan 6 (Reuters) - Ligand Pharmaceuticals Inc  LGND.O :
    * LIGAND’S PARTNER NOVAN SUBMITS NEW DRUG APPLICATION TO THE
U.S.
FDA FOR BERDAZIMER GEL, 10.3% (SB206) FOR THE TREATMENT OF
MOLLUSCUM CONTAGIOSUM
    * LIGAND PHARMACEUTICALS INC - POTENTIAL FDA APPROVAL
ANTICIPATED
IN Q1 OF 2024, ASSUMING FDA FILING ACCEPTANCE AND STANDARD
REVIEW TIMELINES

Source text for Eikon:  ID:nBw59jmyda 
Further company coverage:  LGND.O 
 ((Reuters.Briefs@thomsonreuters.com;))